Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Recent News

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Recent News

Scailyte Quarterly Update, April 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

Recent News

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Read more

Recent News

01 /04

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

02 /04

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Recent News

04 /04

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Read more

Recent News